Nature:基因缺失为药物研发开路

2017-04-17 佚名 转化医学网

基因缺失可以为基因如何产生作用提供有价值的线索,也可以为药物研发提供新的思路。在巴基斯坦的一项研究中,研究者对10503名成年人开展了关于心脏方面试验,其中1843名参与者至少有一种基因,两份拷贝都存在缺失,近日研究者将报告结果在线发表在Nature上。

基因缺失可以为基因如何产生作用提供有价值的线索,也可以为药物研发提供新的思路。在巴基斯坦的一项研究中,研究者对10503名成年人开展了关于心脏方面试验,其中1843名参与者至少有一种基因,两份拷贝都存在缺失,近日研究者将报告结果在线发表在Nature上。

在此期间,研究者通过抽取参与者的血液实时记录200多种参数数据,其中包括血压、心率、血糖水平、胆固醇、激素含量等。通过研究突变基因缺失如何影响这些参数可以找出那些基因可以作为新药研发潜在的有效靶点。默克制药人类遗传学家Robert Plenge表示,将这些遗传数据和医学记录结合可以为将来的许多临床应用提供有效的数据集。

“以往科学家通过敲除小鼠的基因了解到基因编码异常可以影响小鼠的生长发育和行为表现。目前仍需要进行类似的动物研究,但对自然缺失某些特定基因的人类进行这样的研究对于探明人类疾病的基因基础则具有不同寻常的意义。”在Nature同期的一篇评论文章中,Plenge如此写道。

通常情况下,每个人会从父母一方中各继承一个破损拷贝和一个健康拷贝。但在这项研究中,39%的参与者具有近亲关系,基本上为堂(表)兄弟姐妹,这大大增加了子代遗传两份突变拷贝的概率。在1843名参与者中,有1504名存在两份基因拷贝均存在单个基因缺失的现象,其余则至少有一个基因缺失。有位参与者经预测其中6个基因缺乏功能。



在这项研究中,Sekar Kathiresan和他的团队发现有位参与者的两份APOC3基因拷贝均存在失活突变,而他们先前就已经发现有一份APOC3突变拷贝的人更不容易得心脏疾病。ApoC3蛋白可以阻止膳食脂肪被人体代谢清除。有一份突变拷贝的人体内脂肪更容易被消除,减少堵塞在动脉血栓的量。科学家们认为,使ApoC3蛋白失活的药物也可以降低具有两个有效拷贝的个体心脏病发作的风险。

但是有一个问题。科学家担心完全消除ApoC3蛋白活性的药物可能是危险的。先前涉及20多万人的基因组学研究并没有遇到存在两个拷贝APOC3均缺失的个体,这表明人们可能不能完全没有这种基因。而对血液中几乎完全不存在ApoC3蛋白的个体研究发现没有这种蛋白似乎并没有什么不好。

研究人员对1位男性参与者的28个家族成员进行了进一步的研究,这名男子两份拷贝APOC3缺失,他的妻子(他的表/堂妹)和9个孩子也缺失APOC3。研究人员让这个家族中的13个参与者(6个缺失APOC3,7个两份基因拷贝正常)吃奶昔,两份基因拷贝正常的参与者吃完后6小时内甘油三酯的水平飙升了2到3倍,而基因缺失的参与者甘油三酯水平未发生变化。这项结果表明APOC3可能成为心脏病和高血脂药物治疗的一个明确靶标。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987037, encodeId=be9a198e037f6, content=<a href='/topic/show?id=8ea3418e3d4' target=_blank style='color:#2F92EE;'>#基因缺失#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41873, encryptionId=8ea3418e3d4, topicName=基因缺失)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sat Mar 03 07:23:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881908, encodeId=85d81881908bf, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 06 04:23:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300005, encodeId=dd5c13000058c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Apr 19 10:23:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301441, encodeId=cfe3130144123, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Apr 19 10:23:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188435, encodeId=8bf618843585, content=很多药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8732047543, createdName=wen2009, createdTime=Tue Apr 18 07:57:06 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1987037, encodeId=be9a198e037f6, content=<a href='/topic/show?id=8ea3418e3d4' target=_blank style='color:#2F92EE;'>#基因缺失#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41873, encryptionId=8ea3418e3d4, topicName=基因缺失)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sat Mar 03 07:23:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881908, encodeId=85d81881908bf, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 06 04:23:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300005, encodeId=dd5c13000058c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Apr 19 10:23:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301441, encodeId=cfe3130144123, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Apr 19 10:23:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188435, encodeId=8bf618843585, content=很多药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8732047543, createdName=wen2009, createdTime=Tue Apr 18 07:57:06 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-09-06 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1987037, encodeId=be9a198e037f6, content=<a href='/topic/show?id=8ea3418e3d4' target=_blank style='color:#2F92EE;'>#基因缺失#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41873, encryptionId=8ea3418e3d4, topicName=基因缺失)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sat Mar 03 07:23:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881908, encodeId=85d81881908bf, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 06 04:23:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300005, encodeId=dd5c13000058c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Apr 19 10:23:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301441, encodeId=cfe3130144123, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Apr 19 10:23:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188435, encodeId=8bf618843585, content=很多药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8732047543, createdName=wen2009, createdTime=Tue Apr 18 07:57:06 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-19 lqvr
  4. [GetPortalCommentsPageByObjectIdResponse(id=1987037, encodeId=be9a198e037f6, content=<a href='/topic/show?id=8ea3418e3d4' target=_blank style='color:#2F92EE;'>#基因缺失#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41873, encryptionId=8ea3418e3d4, topicName=基因缺失)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sat Mar 03 07:23:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881908, encodeId=85d81881908bf, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 06 04:23:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300005, encodeId=dd5c13000058c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Apr 19 10:23:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301441, encodeId=cfe3130144123, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Apr 19 10:23:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188435, encodeId=8bf618843585, content=很多药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8732047543, createdName=wen2009, createdTime=Tue Apr 18 07:57:06 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1987037, encodeId=be9a198e037f6, content=<a href='/topic/show?id=8ea3418e3d4' target=_blank style='color:#2F92EE;'>#基因缺失#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41873, encryptionId=8ea3418e3d4, topicName=基因缺失)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sat Mar 03 07:23:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881908, encodeId=85d81881908bf, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 06 04:23:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300005, encodeId=dd5c13000058c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Apr 19 10:23:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301441, encodeId=cfe3130144123, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Apr 19 10:23:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188435, encodeId=8bf618843585, content=很多药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8732047543, createdName=wen2009, createdTime=Tue Apr 18 07:57:06 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-18 wen2009

    很多药物

    0

相关资讯

Nat Commun:你的基因决定了你的脸

人类面部特征千变万化,人类学家长使用这种变异来研究人群多样化,包括这些特征因为适应影响而发生改变的可能性。还有人提出,人脸的多样性可能会发生部分演变,以帮助个体识别,这是社会互动的一个重要方面。

PLos One:拇趾外翻不仅仅是因为穿高跟鞋的原因哦!

骨关节炎(OA)是一种最常见的退行性关节疾病,目前已经证,明遗传因素在其病因学中起重要作用。由于步行过程中重复的机械应力,第一个跖趾关节(MTP I)对OA的发展非常敏感。近期,一项发表在杂志PLos One上的研究使用整个外显子测序来研究遗传缺陷,诱发以常染色体显性方式遗传的家族性早发性双侧MTP I OA。此项研究发现,TUFT1基因中的非同义单核苷酸变体rs41310883(c.524C&g

Gastroenterology:食管癌患者组织基因变化

IEN和ESCCS都有类似的突变和基因组不稳定标志,在癌前病变中观察到的基因组变化可能被用来评估食管鳞癌患者的风险

AM J HUM GENET: OTUD6B基因双等位变异可导致智力障碍综合征

泛素化是一种翻译后修饰,调节许多细胞过程,包括蛋白质降解,细胞内运输,细胞信号传导和蛋白质-蛋白质相互作用。颠换泛素化过程的泛素化酶(DUBs)是泛素系统的重要调节因子。OTUD6B编码了含有脱蛋白酶的亚类的卵巢肿瘤结构域(OTU)成员。

Nature:基因揭开巴基斯坦小渔村里心血管的健康秘密

人类有自然发生的基因敲除科学家经常用基因敲除的小鼠来了解基因的功能。在人类中自然发生的“基因敲除”是指从父母中继承了两个非活性的拷贝,而导致基因失活。4月12日的Nature在线报道了超过1800个人携带的“基因敲除”。这是宾夕法尼亚大学医学院的研究人员领导的一项国际合作项目。该计划迄今为止已经对超过10500名居住在巴基斯坦的成年人的蛋白质编码区进行了测序。它揭示了几种不同疾病的基本生物学和可能

Mol Psychiatry.:基因研究为智力障碍精准治疗提供可能

就目前而言,大多数智力障碍患者仍然缺乏有效的分子诊断手段,这对他们的生命健康而言是严重不利的。令人感到惊喜的是,近日成瘾与心理健康中心(CAMH)和皇后大学的科学家们已经最新确定了26个与智力障碍有关的新基因。